Published in Cancer Weekly, June 20th, 2000
The therapy uses the company's innovative Atrigel drug delivery system to administer a 30-day sustained release of leuprolide acetate subcutaneously, an easier and more patient-friendly route of administration than the deep intramuscular injections currently used.
A total of 120 patients are now enrolled in the multi-center, Phase III clinical trial, which is expected to be completed by the end of 2000. The company plans to submit a New Drug Application (NDA) for the new...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.